220 related articles for article (PubMed ID: 25119106)
1. The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.
Liu X; Yuan H; Peres L; Chen S; Chen Z; de The H; Zhou J; Zhu J
PLoS One; 2014; 9(8):e104906. PubMed ID: 25119106
[TBL] [Abstract][Full Text] [Related]
2. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
[TBL] [Abstract][Full Text] [Related]
3. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
4. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
5. A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins.
Zhong S; Delva L; Rachez C; Cenciarelli C; Gandini D; Zhang H; Kalantry S; Freedman LP; Pandolfi PP
Nat Genet; 1999 Nov; 23(3):287-95. PubMed ID: 10610177
[TBL] [Abstract][Full Text] [Related]
6. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
7. PML-RARA fusion transcripts in irradiated and normal hematopoietic cells.
Quina AS; Gameiro P; Sá da Costa M; Telhada M; Parreira L
Genes Chromosomes Cancer; 2000 Nov; 29(3):266-75. PubMed ID: 10992301
[TBL] [Abstract][Full Text] [Related]
8. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation.
Yang S; Jeong JH; Brown AL; Lee CH; Pandolfi PP; Chung JH; Kim MK
J Biol Chem; 2006 Sep; 281(36):26645-54. PubMed ID: 16835227
[TBL] [Abstract][Full Text] [Related]
9. Role of the promyelocytic leukaemia protein in cell death regulation.
Salomoni P; Dvorkina M; Michod D
Cell Death Dis; 2012 Jan; 3(1):e247. PubMed ID: 22237204
[TBL] [Abstract][Full Text] [Related]
10. PML::RARA and GATA2 proteins interact via DNA templates to induce aberrant self-renewal in mouse and human hematopoietic cells.
Katerndahl CDS; Rogers ORS; Day RB; Xu Z; Helton NM; Ramakrishnan SM; Miller CA; Ley TJ
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2317690121. PubMed ID: 38648485
[TBL] [Abstract][Full Text] [Related]
11. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation.
Kamashev D; Vitoux D; De Thé H
J Exp Med; 2004 Apr; 199(8):1163-74. PubMed ID: 15096541
[TBL] [Abstract][Full Text] [Related]
12. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia.
Grimwade D; Solomon E
Curr Top Microbiol Immunol; 1997; 220():81-112. PubMed ID: 9103677
[TBL] [Abstract][Full Text] [Related]
14. Acute promyelocytic leukemia cases with nonreciprocal PML/RARa or RARa/PML fusion genes.
Lafage-Pochitaloff M; Alcalay M; Brunel V; Longo L; Sainty D; Simonetti J; Birg F; Pelicci PG
Blood; 1995 Mar; 85(5):1169-74. PubMed ID: 7858248
[TBL] [Abstract][Full Text] [Related]
15. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
16. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
[TBL] [Abstract][Full Text] [Related]
17. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
Dos Santos GA; Kats L; Pandolfi PP
J Exp Med; 2013 Dec; 210(13):2793-802. PubMed ID: 24344243
[TBL] [Abstract][Full Text] [Related]
18. A sumoylation site in PML/RARA is essential for leukemic transformation.
Zhu J; Zhou J; Peres L; Riaucoux F; Honoré N; Kogan S; de Thé H
Cancer Cell; 2005 Feb; 7(2):143-53. PubMed ID: 15710327
[TBL] [Abstract][Full Text] [Related]
19. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
[TBL] [Abstract][Full Text] [Related]
20. The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha.
Occhionorelli M; Santoro F; Pallavicini I; Gruszka A; Moretti S; Bossi D; Viale A; Shing D; Ronzoni S; Muradore I; Soncini M; Pruneri G; Rafaniello P; Viale G; Pelicci PG; Minucci S
Leukemia; 2011 May; 25(5):814-20. PubMed ID: 21331069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
